Abstract
The biology of cancer is characterized by an intricate interplay of cells originating not only from the tumor mass, but also its surrounding environment. Different microbial species have been suggested to be enriched in tumors and the impacts of these on tumor phenotypes is subject to intensive investigation. For these efforts, model systems that accurately reflect human–microbe interactions are rapidly gaining importance. Here we present a guide for selecting a suitable in vitro co-culture platform used to model different cancer–microbiome interactions. Our discussion spans a variety of in vitro models, including 2D cultures, tumor spheroids, organoids, and organ-on-a-chip platforms, where we delineate their respective advantages, limitations, and applicability in cancer microbiome research. Particular focus is placed on methodologies that facilitate the exposure of cancer cells to microbes, such as organoid microinjections and co-culture on microfluidic devices. We highlight studies offering critical insights into possible cancer–microbe interactions and underscore the importance of in vitro models in those discoveries. We anticipate the integration of more complex microbial communities and the inclusion of immune cells into co-culture systems to more accurately simulate the tumor microenvironment. The advent of ever more sophisticated co-culture models will aid in unraveling the mechanisms of cancer-microbiome interplay and contribute to exploiting their potential in novel diagnostic and therapeutic strategies.
| Original language | English |
|---|---|
| Pages (from-to) | 2053-2067 |
| Number of pages | 15 |
| Journal | International Journal of Cancer |
| Volume | 156 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published Online - 23 Dec 2024 |
Funding
Kamil Moskal, Nimisha Khurana, Luisa Siegert, and Ye Seul Lee are supported by the Helmholtz Foundation and the DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Germany. Kamil Moskal is also supported by the European Research Council THRIVE consortium of the HORIZON-MISS-2023-CANCER program (agreement number 101136622). Eran Elinav is supported by the Leona M. and Harry B. Helmsley Charitable Trust; Adelis Foundation; Ben B. And Joyce E. Eisenberg Foundation; Estate of Bernard Bishin for the WIS-Clalit Program; Jeanne and Joseph Nissim Center for Life Sciences Research; Miel de Botton; Swiss Society Institute for Cancer Prevention Research; Belle S. and Irving E. Meller Center for the Biology of Aging; Sagol Institute for Longevity Research; Sagol Weizmann-MIT Bridge Program; Norman E. Alexander Family M Foundation Coronavirus Research Fund; Mike and Valeria Rosenbloom Foundation; Daniel Morris Trust; Isidore and Penny Myers Foundation; Vainboim Family; and by grants funded by the European Research Council; Israel Science Foundation; Israel Ministry of Science and Technology; Israel. Ministry of Health; the German-Israeli Helmholtz International Research School: Cancer-TRAX (HIRS-0003); Helmholtz Association's Initiative and Networking Fund; Minerva Foundation; Garvan Institute; European Crohn's and Colitis Organization; Deutsch-Israelische Projektkooperation; IDSA Foundation; WIS-MIT grant; Emulate; Charlie Teo Foundation; Mark Foundation for Cancer Research, and Welcome Trust. Eran Elinav is the incumbent of Sir Marc and Lady Tania Feldmann Professorial Chair of Immunology; a senior fellow, Canadian Institute of Advanced Research; and an international scholar, The Bill & Melinda Gates Foundation and Howard Hughes Medical Institute. Jens Puschhof is supported by a European Research Council Starting Grant (agreement number: 101164510), the Helmholtz Foundation, the DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Germany, Emulate Inc., and the European Research Council THRIVE consortium of the HORIZON-MISS-2023-CANCER program (agreement number 101136622). Open Access funding enabled and organized by Projekt DEAL.
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research